JAMA+ AI is a window into the scientific content, educational reviews, and commentary on AI & medicine published across the @JAMANetwork family of journals.
Announcing the launch of JAMA+ AI, an engaging, interactive channel that amplifies the best of the JAMA Network’s content exploring the science of artificial intelligence and digital medicine and its application in health and health care. ja.ma/3By7x4t
🎙️ In this episode of JAMA+ AI Conversations, Yulin Hswen, ScD, MPH, spoke with Bon Ku, MD, MPP, program manager at @ARPA_H about how simulation-based testing may help assess artificial intelligence systems before they are used in real-world care.
ja.ma/3VPgoZF
📊 Research Summary: Among adults with established #atherosclerotic#cardiovascular disease or high cardiovascular risk and recent #Statin nonadherence, digital outreach improved 14-day statin refill vs usual communication.
ja.ma/4cNvBAm
💬 Editorial: Digital outreach by nonsecure email, short message service, or secure portal messaging improved #Statin refill rates among patients with established atherosclerotic cardiovascular disease or high #cardiovascular risk and recent nonadherence.
ja.ma/4h5y5Ls
➡️ Interested in learning more about the role of artificial intelligence and digital #medicine in #health care?
Follow @JAMAplusAI and subscribe to the newsletter for accessible, timely #AI content: ja.ma/4rbUXxQ
Trying to build your #AI knowledge?
The JAMA+ AI Editors have curated resources to understand key concepts in AI in medicine, along with must-read AI articles from across the JAMA Network.
📌 Explore JAMA+ AI Resources: ja.ma/4qY3HqV
💬 Editor's Note by JAMA Deputy Editors Preeti Malani, MD, MSJ, and Joseph Ross, MD, MHS: As generative #AI tools become more advanced and accessible, transparent reporting and updated editorial guidance are needed to ensure research integrity.
ja.ma/3UxO65y
JAMA+ AI is a window into the reviews and commentary on AI and medicine published across JAMA, JAMA Network Open, and the 11 JAMA specialty journals.
Editor in Chief Roy Perlis, MD, MSc, curates the content delivered directly to your inbox.
Learn more: jamanetwork.com/channels/ai
💬 Perspective: Much of today’s #WearableData may function as results of unknown significance, appearing clinically useful without clear evidence, reference ranges, or defined roles in diagnosis and treatment.
ja.ma/4qirYrJ
ALT JAMA article published August 3, 2026, titled \"Sorting Results of Unknown Significance\u2014A Framework for Clinicians Navigating Wearable Data in the AI Era.\" It features a table classifying patient-generated and device-derived health data by clinical validity and recommended clinical actionability.
💬 Viewpoint: Under the US Food and Drug Administration January 2026 guidance, many low-risk #DigitalHealth tools fall outside medical device oversight, but some may still influence health decisions without clear evidence standards.
ja.ma/4fWTCHa
🎙️@JAMAplusAI Conversations: JAMA+ AI Editor in Chief Roy Perlis, MD, MSc, and Joseph Geraci, PhD, discussed how artificial intelligence may shape #ClinicalTrials and how regulators may evaluate trials using #AI#biomarkers.
🔗 ja.ma/4wY1YUX
💬 Perspective: #GenerativeAI may improve #ClinicalDecisionSupport when it synthesizes decision-relevant patient context, but outputs should remain grounded in curated sources with source attribution and deterministic verification.
ja.ma/4g4LEdK
ALT JAMA article by Liu, Peterson, Wright, published July 23, 2026. A flowchart titled 'How Generative AI Should Transform Clinical Decision Support' compares current Clinical Decision Support (CDS) with LLM-enabled CDS across data, delivery, and governance, also outlining key risks.
💬 Editor's Note by JAMA Executive Editor Gregory Curfman, MD: The @FDA and the Federal Trade Commission provide limited oversight for low-risk #DigitalHealth wellness devices, aiming to preserve innovation while requiring truthful, substantiated claims.
ja.ma/4z9DDNw
💬 Editor's Note by JAMA Deputy Editors Preeti Malani, MD, MSJ, and Joseph Ross, MD, MHS: As generative #AI tools become more advanced and accessible, transparent reporting and updated editorial guidance are needed to ensure research integrity.
ja.ma/4wBdEwx
Ambient #AI scribes now #automate documentation and #clinical assessments, offering time savings and reduced burnout, but raise important questions about oversight, automation bias, and accountability.
🔗 ja.ma/4blN3v6
In the latest episode of the #HealthyDialogue podcast, JAMA Senior Editor Derek Angus, MD, MPH, and Vincent Liu, MD, MS, discuss the evolution of ambient #AI scribes in #health care.
🔗 ja.ma/4blN3v6